Radalbuvir ( GS 9669 )

产品货号. M11266 CAS No. 1314795-11-3

Radalbuvir (GS-9669) is a highly optimized thumb site II nonnucleoside inhibitor of HCV NS5B polymerase with binding affinity of 1.35 nM for genotype 1b.

纯度: >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

规格	价格/人民币	库存	数量
5MG	￥11907	有现货
50MG	￥24138	有现货
100MG	￥32400	有现货
200MG	获取报价	有现货
500MG	获取报价	有现货
1G	获取报价	有现货

拼团产品询价大包装询价加入购物车

生物学信息

产品名称

Radalbuvir
注意事项

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
产品简述

Radalbuvir (GS-9669) is a highly optimized thumb site II nonnucleoside inhibitor of HCV NS5B polymerase with binding affinity of 1.35 nM for genotype 1b.
产品描述

Radalbuvir (GS-9669) is a highly optimized thumb site II nonnucleoside inhibitor of HCV NS5B polymerase with binding affinity of 1.35 nM for genotype 1b; shows inhibition of WT genotype 1b replicon and NS5B M423T mutant replicon with EC50 of 6 nM and 12 nM respectively.
同义词

GS 9669
通路

Microbiology/Virology
靶点

HCV
受体

HCV
研究领域

——
适应症

——

化学信息

CAS Number

1314795-11-3
分子量

543.72
分子式

C30H41NO6S
纯度

>98% (HPLC)
溶解度

——
SMILES

CC1=CCC(CC1)C(=O)N(C2CCC(CC2)(COC3CCOC3)O)C4=C(SC(=C4)C#CC(C)(C)C)C(=O)O
化学全称

2-Thiophenecarboxylic acid, 5-(3,3-dimethyl-1-butyn-1-yl)-3-((cis-4-hydroxy-4-((((3S)-tetrahydro-3-furanyl)oxy)methyl)cyclohexyl)(((1R)-4-methyl-3-cyclohexen-1-yl)carbonyl)amino)-

运输与储存

储存条件

(-20℃)
运输条件

With Ice Pack
稳定性

≥ 2 years

参考文献

1. Lazerwith SE, et al. J Med Chem. 2014 Mar 13;57(5):1893-901.
2. Fenaux M, et al. Antimicrob Agents Chemother. 2013 Feb;57(2):804-10.
3. Dvory-Sobol H, et al. Antimicrob Agents Chemother. 2014 Nov;58(11):6599-606.

计算器

浓度计算器

摩尔计算器

分子量计算器

产品手册

关联产品

7-benzyl-5,6-dimethy...

Oxytetracycline (OTC) is a broad-spectrum antibiotic that acts by inhibiting protein synthesis in D2401bacteria.
Anguizole

Anguizole is a HCV NS4B inhibitor targeting second amphipathic helix of NS4B (NS4B-AH2).
Nucleoside-Analog-2

A 4′-azidocytidine analogue that shows anti-HCV activity.

Product			Quantity Required*
Name *			E-mail Address *
Organization *			Phone Number
Remarks